34
nanotimes
Companies Facts
trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with
E.Coli and Pseudomonas to follow in early 2011.
Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in ap- proximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contri- bute to the fight against GBS antibiotic resistance.
http://www.nanologix.com
http://www.epa.gov/microbes/mceardnewsarchive.html
http://www.uthouston.edu/media/newsreleases/nr2010/ index.htm?id=2434326
European Society of Cardiology, demonstrates the value of using Nanosphere‘s (NASDAQ: NSPH) Ve- risens™ cTnI assay (RUO) to detect very low levels of troponin I in hospitalized patients with heart failure.
A
The research, conducted at the Veterans Affairs (VA) Hospital in San Diego, was part of the „Veterans Af- fairs Effects of Therapy“ study. In addition to the VA, there were investigators from UCSD and the Cleve- land Clinic. The study employing the Verisens™ assay for troponin I involved 144 patients discharged with acute heart failure, who were followed for 90 days.
clinical study released online by the European Journal of Heart Failure, a publication of the
Both the BNP and the Verisens™ cTnI assay were te- sted on blood drawn at admission, discharge, and up to four consecutive days while hospitalized. The new Verisens™ cTnI assay could quantitatively measure troponin I in more than 99% of blood samples. Even at low concentrations, troponin I in the higher quar- tiles identified increased risk of death and re-hos- pitalization for patients. Additionally, patients who had rising levels at any concentration while treated in the hospital, had a higher risk of death. Of further note, these results were statistically significant for the Verisens™ cTnI assay, but not for BNP. Yang Xue, Paul Clopton, William F. Peacock and Alan S. Maisel: Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure, In: Oxford Journals Medicine, European Journal of Heart Failure, Volume 13(2010), Issue1, January 2011, Pages 37-42, DOI:10.1093/eurjhf/hfq210:
http://dx.doi.org/10.1093/eurjhf/hfq210
http://www.nanosphere.us N
anostart AG (OTCQX: NASRY) is investing in Microlight Sensors Pte Ltd. The company,
which is headquartered in Singapore, designs, de- velops and assembles fully-integrated optical sensor and scanning systems for specialty applications in the homeland security and commercial spectral instrumentation systems market. Microlight’s unique high-end optical systems are attributed to its proprie- tary sensor designs and in-house professional team of optical designers and engineers, providing Microlight the capabilities to “tailor-make” optical systems with strict quality assurance controls for customers. Micro- light has developed strong active partnerships with institutions and customers worldwide.
11-01 :: December 2010 / January 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95